RxDoctor Payments Data

Donna Dundon

Family · Scottsdale, AZNPI 1972666295

Payments from drug & device makers

$2,729in general payments, 2019–2025

Across 85 payments — averaging $32.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$664
  • Novartis$405
  • AbbVie$392
  • UCB, Inc.$292
  • Argenx US, Inc.$169
  • Acadia Pharmaceuticals Inc$125
  • plus $683 from 21 others

What the payments were for

  • Food & beverage$2,70599%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,729 in reported general payments places this provider in the 85th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab39$340,723
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5016$186,857
RebifInterferon Beta-1a/Albumin17$178,773
VumerityDiroximel Fumarate13$128,982
CopaxoneGlatiramer Acetate12$84,619
RytaryCarbidopa/Levodopa40$50,565
UbrelvyUbrogepant29$35,479
Nurtec OdtRimegepant Sulfate26$33,188
Glatiramer Acetate13$30,999
Emgality PenGalcanezumab-Gnlm43$29,908
Dimethyl Fumarate16$24,588
Galantamine ErGalantamine Hbr193$14,375
Hysingla ErHydrocodone Bitartrate13$11,399
Zembrace SymtouchSumatriptan Succinate13$10,383
Dalfampridine ErDalfampridine31$8,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$26$186,85716 claims
BiogenVumerity$664$128,98213 claims
Teva Pharmaceuticals USA, Inc.Copaxone$66$84,61912 claims
AbbVieUbrelvy$392$35,47929 claims
PfizerNurtec Odt$34$33,18826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,119 family providers in Arizona.

Other family in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →